新的血液学反应标准可预测接受大剂量美法仑和自体干细胞移植治疗的免疫球蛋白轻链淀粉样变性患者的生存率。 - Suppr

Suppr

超能文献

New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation.

作者信息

Girnius Saulius, Seldin David C, Cibeira Maria Teresa, Sanchorawala Vaishali

出版信息

J Clin Oncol. 2013 Jul 20;31(21):2749-50. doi: 10.1200/JCO.2013.48.7736. Epub 2013 Jun 17.

DOI:10.1200/JCO.2013.48.7736

PMID:23775968

Abstract

摘要

相似文献

New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation.新的血液学反应标准可预测接受大剂量美法仑和自体干细胞移植治疗的免疫球蛋白轻链淀粉样变性患者的生存率。

J Clin Oncol. 2013 Jul 20;31(21):2749-50. doi: 10.1200/JCO.2013.48.7736. Epub 2013 Jun 17.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation.新的轻链淀粉样变反应标准有助于对自体造血细胞移植后100天的患者进行风险分层。

Biol Blood Marrow Transplant. 2016 Apr;22(4):768-770. doi: 10.1016/j.bbmt.2015.12.021. Epub 2015 Dec 29.

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.基于游离轻链检测和心脏生物标志物的免疫球蛋白轻链淀粉样变治疗反应新标准：对生存结局的影响。

J Clin Oncol. 2012 Dec 20;30(36):4541-9. doi: 10.1200/JCO.2011.37.7614. Epub 2012 Oct 22.

Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.移植前新型药物诱导可预测接受大剂量美法仑和自体干细胞移植的免疫球蛋白轻链淀粉样变性患者的无进展生存期。

Amyloid. 2016 Dec;23(4):254-259. doi: 10.1080/13506129.2016.1258356. Epub 2016 Nov 23.

[The clinical significance of serum free light chain in primary systemic amyloidosis].[血清游离轻链在原发性系统性淀粉样变中的临床意义]

Zhonghua Nei Ke Za Zhi. 2011 May;50(5):404-7.

High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.VAD诱导化疗后大剂量美法仑联合自体干细胞移植治疗轻链型淀粉样变性：一项单中心前瞻性II期研究

Br J Haematol. 2004 Dec;127(5):543-51. doi: 10.1111/j.1365-2141.2004.05232.x.

Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.免疫球蛋白轻链淀粉样变性：2014 年诊断、预后和治疗更新。

Am J Hematol. 2014 Dec;89(12):1132-40. doi: 10.1002/ajh.23828.

High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.大剂量美法仑与自体干细胞移植治疗系统性轻链型淀粉样变性：单中心40例回顾性分析

Int J Hematol. 2016 Mar;103(3):299-305. doi: 10.1007/s12185-015-1922-x. Epub 2015 Dec 24.

High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.高剂量美法仑与美法仑加地塞米松治疗AL淀粉样变性

N Engl J Med. 2007 Sep 13;357(11):1083-93. doi: 10.1056/NEJMoa070484.

Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.基线蛋白尿的严重程度可预测自体干细胞移植后免疫球蛋白轻链相关淀粉样变性的肾脏反应。

Clin J Am Soc Nephrol. 2007 May;2(3):440-4. doi: 10.2215/CJN.02450706. Epub 2007 Apr 4.

引用本文的文献

Prognostic Implication of Longitudinal Changes of Left Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis.化疗后心脏轻链淀粉样变患者左心室整体应变纵向变化的预后意义

Front Cardiovasc Med. 2022 Jun 24;9:904878. doi: 10.3389/fcvm.2022.904878. eCollection 2022.

[Primary light chain amyloidosis onset with acquired FX deficiency: a case report and literature review].[原发性轻链淀粉样变性伴获得性FX缺乏症发病：一例报告及文献复习]

Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):680-682. doi: 10.3760/cma.j.issn.0253-2727.2020.08.012.

Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure.心力衰竭相关轻链心脏淀粉样变患者的死亡率预测因素。

Sci Rep. 2019 Jun 12;9(1):8552. doi: 10.1038/s41598-019-44912-x.

Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.轻链型可预测接受干细胞移植的淀粉样变性患者的器官受累和生存情况。

Blood Adv. 2018 Apr 10;2(7):769-776. doi: 10.1182/bloodadvances.2018016782.

[How I treat immunoglobulin light chain amyloido-sis].[我如何治疗免疫球蛋白轻链淀粉样变性]

Zhonghua Xue Ye Xue Za Zhi. 2017 Jun 14;38(6):469-474. doi: 10.3760/cma.j.issn.0253-2727.2017.06.002.

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.口服蛋白酶体抑制剂伊沙佐米用于复发或难治性AL淀粉样变性的1/2期研究。

Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26.

[The consensus of the diagnosis and treatment of primary light chain amyloidosis in China (2016 version)].《中国原发性轻链型淀粉样变性诊断与治疗专家共识（2016年版）》

Zhonghua Xue Ye Xue Za Zhi. 2016 Sep 14;37(9):742-746. doi: 10.3760/cma.j.issn.0253-2727.2016.09.003.

Biol Blood Marrow Transplant. 2016 Apr;22(4):768-770. doi: 10.1016/j.bbmt.2015.12.021. Epub 2015 Dec 29.

Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.严格的患者选择可改善初治及复发情况下自体干细胞移植后系统性轻链淀粉样变性的治疗效果。

Haematologica. 2014 Dec;99(12):e260-3. doi: 10.3324/haematol.2014.108191. Epub 2014 Sep 5.

Update on treatment of light chain amyloidosis.轻链淀粉样变性治疗进展。

Haematologica. 2014 Feb;99(2):209-21. doi: 10.3324/haematol.2013.087619.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验